Table 4.
Treatment options in different groups
| Type I-IS N = 61 |
aType II IS N = 6 |
Type III IS N = 8 |
bMS-DMD N = 10 |
|||
|---|---|---|---|---|---|---|
| AZT N = 19 |
MMF N = 12 |
RTX N = 30 |
||||
| Therapy choice, n (%) | ||||||
| First line | 15 (78.9) | 6 (50) | 19 (63.3) |
5 (83.3) (3 CYC, 1 MTX, 1 MiTX) |
5 (62.5) (3 CS, 2 IVIG) |
10 (100) (6 IFN, 1 TFN, 1 GA, 2 NTZ) |
| Second line | 3 (15.8) | 5 (41.7) | 5 (16.6) |
1 (16.6) (1 MTX) |
3 (37.5) (3 CS) |
– |
| Other lines | 1 (5.3) | 1 (8.3) | 6 (29.4) | – | – | |
| Patients discontinuing treatment, n (%) | 9 (47.4) | 7 (58.3) | 3 (10) | 6 (100) | 5 (55.6) | 7 (70) |
| Causes for discontinuing treatment, n (%) | ||||||
| General intolerance | 2 (22.2) | 1 (14.3) | 1 (33.3) | – | – | 1 (14.3) |
| Biological intolerance | 2 (22.2) | – | – | 1 (16.7) | – | – |
| Physician decision | 2 (22.2) | 2 (28.6) | 1 (33.3) | 3 (50) | 4 (80) | 1 (14.3) |
| Patient decision | 1 (11.1) | – | – | – | – | – |
| Treatment failure | 2 (22.2) | 4 (57.1) | 1 (33.3) | 2 (33.3) | 1 (20) | 4 (57.1) |
| Pregnancy desire | – | – | – | – | – | 1 (14.3) |
a One patient switched from CYC to MTX
bThree patients switched from MS-DMD to another MS-DMD
IS immunosuppressants, MS-DMD multiple sclerosis disease-modifying drugs, AZT azathioprine, MMF mycophenolate mophetile, RTX rituximab, CS corticoids, CYC cyclophosphamide, IVIG intravenous immunoglobulins, MTX methotrexate, MiTX mitoxantrone, IFN interferon, TNF teriflunomide, GA glatiramer acetate, NTZ natalizumab